On August 15, 2024, Neptune Medical, a leader in medical device innovation, announced the completion of a $97 million Series D financing. Sonder Capital and Olympus Corporation of the Americas were significant participants in the round, which included investments from other existing and new investors. Wilson Sonsini Goodrich & Rosati advised Neptune Medical on the transaction.

The financing will strengthen Neptune Medical as a gastrointestinal-focused company expanding into robotics for GI disease, as evidenced by the recent appointment of medical robotics pioneer Dr. Fred Moll as chairman of the company’s board.

Neptune Medical also announced the successful spinout of its subsidiary, Jupiter Endovascular, which is developing a new class of endovascular procedures to bring the precision and control of direct surgical access to catheter-based interventions. Wilson Sonsini will represent Jupiter Endovascular moving forward.

The Wilson Sonsini team that advised Neptune Medical on the Series D financing included James Huie, Brian Appel, MJ Han, and Ryan Isola.

For more information, please see Neptune Medical’s news release. Additional coverage is available in Fierce Biotech.